- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05334849
Prospectively Predict the Immunotherapy Response of Gastric Cancer Based on Circulating Exosomal LncRNA-GC1 Biopsy
Prospectively Predict the Efficacy of Precise Immunotherapy Response of Gastric Cancer Based on Circulating Exosomal LncRNA-GC1 Biopsy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The investigator's previous work identified circulating exosomal lncRNA-GC1 as a GC-specific tumor burden marker and this novel biomarker showed promising efficiency in monitoring disease progression during treatment.
Hence in this stuty, the investigator plan to recruit a prospective cohort to support the conclusions, and provide biomarkers to realize predicting and monitoring immunotherapeutic outcomes of GC.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100853
- Chinese PLA General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Having signed informed consent
- Age≥ 18 years old
- Histologically confirmed gastric adenocarcinoma
- Unresectable recurrent or metastatic disease
- Measurable disease according to the RECIST criteria
- Life expectancy of ≥3 month
- No prior chemotherapy of the study more than 4 weeks
- Immunotherapy regimens were included in the treatment
Exclusion Criteria:
- Other previous malignancy within 5 year
- Surgery (excluding diagnostic biopsy) within 4 weeks prior to study
- Pregnancy or lactation period
- Legal incapacity
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Levels of circulating exosomal lncRNA-GC1
Time Frame: Circulating exosomal lncRNA-GC1 was detected, analysis and reported at the baseline
|
Circulating exosomal lncRNA-GC1 was detected by the RT-PCR followed by isolating exosomes.
|
Circulating exosomal lncRNA-GC1 was detected, analysis and reported at the baseline
|
Levels of circulating exosomal lncRNA-GC1
Time Frame: Circulating exosomal lncRNA-GC1 was detected, analysis and reported through study completion, average 1 year
|
Circulating exosomal lncRNA-GC1 was detected by the RT-PCR followed by isolating exosomes.
|
Circulating exosomal lncRNA-GC1 was detected, analysis and reported through study completion, average 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Survival outcomes of circulating exosomal lncRNA-GC1
Time Frame: up to 3 years
|
Analysis participants' survival with different levels of circulating exosomal lncRNA-GC1 detected by RT-PCR.
|
up to 3 years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- irBiomarker
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Immunotherapy
-
Ajou University School of MedicineCompletedImmunotherapyKorea, Republic of
-
The First Affiliated Hospital with Nanjing Medical...Recruiting
-
Centre Georges Francois LeclercAstraZenecaActive, not recruiting
-
Power Life Sciences Inc.Not yet recruitingCancer | Immunotherapy
-
Xuanwu Hospital, BeijingRecruitingImmunotherapy | ADRChina
-
Rutgers, The State University of New JerseyPfizer; American Cancer Society, Inc.CompletedImmunotherapy | Clinical TrialsUnited States
-
Peking University First HospitalYiZhou International Cancer HospitalUnknownImmunotherapy | Proton Therapy
-
Nanfang Hospital, Southern Medical UniversityRecruitingImmunotherapy | Biomarker | HyperprogressionChina
-
Peking University First HospitalNot yet recruitingImmunotherapy | SBRT | Bulky Tumor
Clinical Trials on Circulating exosomal lncRNA-GC1 detection
-
Lin ChenXijing HospitalRecruiting
-
Chinese PLA General HospitalRecruitingGastric Cancer | Chemotherapy EffectChina
-
Jinshan Hospital Fudan UniversityShanghai Municipal Commission of Health and Family PlanningUnknownDiabetic Peripheral NeuropathyChina
-
Zhongnan HospitalRecruiting
-
Centre Henri BecquerelNot yet recruitingSquamous Cell Carcinoma of the Oral CavityFrance
-
Centre Henri BecquerelNot yet recruitingPeripheral T Cell LymphomaFrance
-
Centre Hospitalier Universitaire de NīmesActive, not recruitingAdenocarcinoma of the ProstateFrance
-
Second Xiangya Hospital of Central South UniversityThe First Affiliated Hospital of Nanchang University; Xiangya Hospital of Central... and other collaboratorsRecruitingLung Cancer, Non-small Cell | Circulating Tumor DNA | EGFR Gene Mutation | EGFR-TKI Resistant Mutation | Primary ResistanceChina
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...CompletedBladder Cancer | Circulating Tumor CellsItaly
-
City of Hope Medical CenterRecruitingGastric Cancer | Gastric Adenocarcinoma | Gastric Cancer Stage IV | Gastric Neoplasm | Gastric Cancer Metastatic to Lung | Gastric Cancer Stage | Gastric Cancer Metastatic to Liver | Gastric Cancer Stage III | Gastric Cancer Stage II | Gastric Lesion | Gastric Cancer in Situ | Gastric Cancer Stage IIIB | Gastric... and other conditionsUnited States, Japan